CB6_PI_EGF). To evaluate the potency of the shRNAs, the 10 pAAV-shRNAs were transfected into QBI-293-A2 cells that transiently expressed mouse PNPLA3-V5 using Lipofectamine 2000 (Invitrogen). An AAV cis plasmid containing the H1 promoter and termination sequence was used as a negative control. After 48 h, cells were harvested and PNPLA3 expression was measured by RT-PCR and immunoblot analysis using an anti-V5 Ab. shRNA8 (5'-TCAGGATCCTGTCCTACATccgaAGATGTAGGACAGGATCCTGC-3') the shRNA that most potently inhibited PNPLA3 expression, was used for AAV production by the University of Massachusetts Medical School Viral Vector Core as previously described (3) .
The optimal dose of AAV for knockdown of PNPLA3 in mouse livers was determined by injecting 10-week old C57BL/6J male mice with increasing amounts of pAAV.shRNA PNPLA3 [1.0, 2.0 3.0 and 4.0 X 10 11 genome copies (GC)]. Mice were fed a high-fructose diet for 14 days, metabolically synchronized for 3 days, and sacrificed at end of the last feeding cycle. LDs were isolated, proteins extracted, and PNPLA3 was detected by immunoblotting.
The following AAV constructs were ordered from Vector Biolabs Inc. 1) Atg7 (AAV8-GFP-U6-M-ATG7-shRNA, Genbank RefSeq: NM_028835). 2) A virus encoding a scrambled mRNA (Scr): AAV8-CMV/GFP-U6-scr-shRNA). 3) Human AAV-PNPLA3 expression constructs that were subcloned into a pAAV-thyroxine binding globulin (TBG) vector backbone (Addgene, Watertown, MA) to provide liver specificity. The sequences of the constructs are available from the vendor.
Analysis of Lipid Droplets
LDs were suspended in solubilization buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, Foscholine13 (0.1%) supplemented with protease inhibitor (Roche)] and incubated at 4°C with mild shaking for 4 h. The suspension was centrifuged at 20,000xg for 30 min at 4°C and the LD proteins were incubated with 50 µl Flag-agarose (Sigma Aldrich) for 4 h at 4°C. Beads were washed 3X in solubilization buffer without detergent. Beads were boiled with 2X sample buffer at 95°C for 5 min and the supernatant was applied to a 12% SDS-PAGE gel and analyzed by immunoblotting. To avoid interference with the immunoglobulin heavy chain, goat anti-rabbit light chain IgG, goat anti-mouse light chain IgG, and Fc fragment-specific horseradish peroxidase-conjugated secondary Abs were used for immunoblotting. The blots were quantified using the LI-COR Odyssey system.
Immunofluorescence Microscopy
QBI-293A cells were cultured in complete medium (DMEM with high glucose, 5% fetal calf serum) and transfected with the indicated plasmids using FuGENE 6 (Promega, Madison, WI). The medium was replaced with new complete medium plus OA (200 µM) 5 h after transfection. After 24 h, cells were rinsed with PBS and then fixed for 15 min in paraformaldehyde (4%). Cells were then incubated with 50 mM NH 4 Cl for 15 min and permeabilized for 2 min using Triton X-100 (0.1%) in FSG buffer [PBS containing fish skin gelatin (0.2%)] (MilliporeSigma, Burlington, MA). After blocking in FSG buffer for 15 min, cells were incubated with the primary Abs in FSG buffer at 4ºC overnight. Cells were rinsed with FSG buffer twice before incubating with the secondary Ab for 35 min at room temperature. LDs were stained using monodansylpentane (1:1,000, MDH, AutoDOT, Abgent, San Diego, CA) for 30 min. Cells on coverslips were immersed in Vectashield anti-fade mounting medium (H-1400, Vector Laboratories, Burlingame, CA) and placed on slides. Cells were visualized using a confocal microscope (Zeiss LSM 880).
Bortezomib Treatment.
Mice fed a HSD ad libitum for 4 weeks were subjected to the synchronization protocol. After the last refeeding cycle, mice were injected via the tail vein with bortezomib (LC Laboratories, Woburn, MA) that was dissolved in ethanol (10 mg/ml) and then diluted 1:20 in saline (0.9% NaCl (w/v). Mice were injected with bortezomib (1 mg/kg) in a volume of 200 µl. Control mice were injected with an equal volume of vehicle alone. The mice were killed 5 h after the injection and livers were harvested for lipid and immunoblot analysis.
Chloroquine Treatment
Mice fed a HSD ad libitum for 4 weeks were subjected to the synchronization protocol and then treated with chloroquine (25 mg/kg diluted in 200 µl PBS) via the tail vein at the end of the last refeeding cycle as described (4) . Mice were killed after 3 h of fasting since chloroquinemediated inhibition of autophagic flux is maximal after 2-4 h (5, 6). Livers were harvested and LDs and lysates were prepared as described (7). Fig. 3 , top panel). LDs were isolated and solubilized, and PNPLA3 was immunoprecipitated from a total of 25 µg of the protein as described in the Methods. A total of one-tenth of the immunoprecipitate was subjected to immunoblotting. The experiment was repeated twice and the result was similar. +/+ and Pnpla3 148M/M mice (n=10/group, aged 7-9 weeks) were fed a high-fructose diet for 2 wks and then subjected to the diet synchronization protocol. LDs were isolated as described in the Supplementary Methods and the proteins (3 µg) were analyzed by immunoblotting using antibodies directed against PNPLA3, CGI-58 and PLIN2. The signals were quantified using LI-COR and the ratios of PNPLA3 and CGI-58 to PLIN2 are provided. Liver TGs were extracted from lysates and measured enzymatically as described in the Methods. The means +/-SE are given. *p<0.05,**p<0.01,***p<0.001. The experiment was repeated once and the results were similar. 
